Anti-secretory and anti-proliferative actions of next-generation dual subtype 2 and 5 somatostatin receptor ligands in neuroendocrine tumor models
Dual SSTR2/SSTR5 agonists exhibit antisecretory and antiproliferative activity in NET models that was similar or even superior to reference SRLs. These findings support their further development as next-generation SRLs for SSTR2/5-expressing tumors.
Authors
- Alan G. Harris (ORCID: https://orcid.org/0000-0002-6618-2092)
- Natalia S. Pellegata (ORCID: https://orcid.org/0000-0002-8000-7784)
- J Schrader
- Frank J. Ascione (ORCID: https://orcid.org/0000-0002-8087-3148)
- Franco Fedeli
- Alessandro Marangelo
- Margarita Bistika
- Fabio L. Guzzi
Institutions
- Universität Hamburg (DE)
- Heidelberg University (DE)
- University of Pavia (IT)
- University Hospital Heidelberg (DE)
- Helmholtz Zentrum München (DE)
- NYU Langone Health (US)
- University Medical Center Hamburg-Eppendorf (DE)
- Diabetesinstitut Heidelberg (DE)
- New York University (US)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2026-02-27
- DOI
- https://doi.org/10.3389/fonc.2026.1766563
- Primary Topic
- Neuroendocrine Tumor Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 0.00